First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors
Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
YL-13027-001 is a phase I open-label, first in human, dose escalation study which investigate
the tolerability, safety, pharmacokinetics (PK) and efficacy of YL-13027 in subjects with
advanced stage solid tumors.